1 | 156053-89-3 | 爱维莫潘 | Alvimopan | C25H32N2O4
| 原料药;药物试剂;医用原料;化工原料;医药原料;医药中间体;小分子抑制剂;对照品-杂质对照品;肠胃泌尿生殖系统类;G蛋白偶联受体&G蛋白 | |
2 | 1217616-62-0 | Alvimopan-d5 | Alvimopan-d5 | C25H32N2O4
| | |
3 | 940941-43-5 | N2-FMOC-L-赖氨酸叔丁酯 | fmoc-l-lys-otbu | C25H32N2O4
| | |
4 | 156130-44-8 | ALVIMOPAN ENANTIOMER | AlviMopan EnantioMer | C25H32N2O4
| | |
5 | 2280856-88-2 | Alvimopan Impurity 25 | Alvimopan Impurity 25 | C25H32N2O4
| | |
6 | 342639-35-4 | ALVIMOPAN DIASTEREOMER 1 | AlviMopan DiastereoMer 1 | C25H32N2O4
| | |
7 | 1261396-48-8 | UPNUIXSCZBYVBB-ZXAJRTDPSA-N | UPNUIXSCZBYVBB-ZXAJRTDPSA-N | C25H32N2O4
| | |
8 | 1451145-30-4 | N6,N6-Diethyl-N2-Fmoc-L-Lysine | N6,N6-Diethyl-N2-Fmoc-L-Lysine | C25H32N2O4
| | |
9 | 865152-27-8 | 2,7-dinitro-9,9-dihexylfluorene | 2,7-dinitro-9,9-dihexylfluorene | C25H32N2O4
| | |
10 | 1593842-75-1 | Nα-Fmoc-Nε-tetr-butyl-L-lysine | Nα-Fmoc-Nε-tetr-butyl-L-lysine | C25H32N2O4
| | |
11 | 660848-76-0 | 阿维莫泮杂质 | Alvimopan-d5 (Mixture of Diastereomers) | C25H32N2O4
| | |
12 | 33514-91-9 | 17β-Hydroxyandrost-4-en-3-one O-(p-nitrophenyl)oxime | 17β-Hydroxyandrost-4-en-3-one O-(p-nitrophenyl)oxime | C25H32N2O4
| | |
13 | | 2,2'-Azobis(2-methyl-4-phenylvaleric acid methyl) ester | 2,2'-Azobis(2-methyl-4-phenylvaleric acid methyl) ester | C25H32N2O4
| | |
14 | 581779-68-2 | methyl 4-{[2-(2-nonanoylcarbohydrazonoyl)phenoxy]methyl}benzoate | methyl 4-{[2-(2-nonanoylcarbohydrazonoyl)phenoxy]methyl}benzoate | C25H32N2O4
| | |
15 | 664311-00-6 | 2-(2-allylphenoxy)-N'-[2-(hexyloxy)-5-methoxybenzylidene]acetohydrazide | 2-(2-allylphenoxy)-N'-[2-(hexyloxy)-5-methoxybenzylidene]acetohydrazide | C25H32N2O4
| | |
16 | 2250436-42-9 | D-Lysine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 1,1-dimethylethyl ester | D-Lysine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 1,1-dimethylethyl ester | C25H32N2O4
| | |
17 | 385420-79-1 | 4-butoxy-N-[1-[(ethylamino)carbonyl]-2-(4-isopropoxyphenyl)vinyl]benzamide | 4-butoxy-N-[1-[(ethylamino)carbonyl]-2-(4-isopropoxyphenyl)vinyl]benzamide | C25H32N2O4
| | |
18 | 1798021-74-5 | 4-[[5-Oxo-5-(phenylmethoxy)pentyl][(phenylmethoxy)carbonyl]amino]-1-piperidine | 4-[[5-Oxo-5-(phenylmethoxy)pentyl][(phenylmethoxy)carbonyl]amino]-1-piperidine | C25H32N2O4
| | |
19 | | N,N-diethyl-2',6'-dimethyltyrosyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid | N,N-diethyl-2',6'-dimethyltyrosyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid | C25H32N2O4
| | |
20 | | N-(2-METHOXYETHYL)-N-[1-(3-PHENYLPROPYL)PIPERIDIN-4-YL]-1,3-BENZODIOXOLE-5-CARBOXAMIDE | N-(2-METHOXYETHYL)-N-[1-(3-PHENYLPROPYL)PIPERIDIN-4-YL]-1,3-BENZODIOXOLE-5-CARBOXAMIDE | C25H32N2O4
| | |
21 | 2519482-21-2 | Benzoic acid, 2-hydroxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]- | Benzoic acid, 2-hydroxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]- | C25H32N2O4
| | |
22 | | N-(4-{[butyl(methyl)amino]carbonyl}phenyl)-4-(4-methoxyphenyl)tetrahydro-2H-pyran-4-carboxamide | N-(4-{[butyl(methyl)amino]carbonyl}phenyl)-4-(4-methoxyphenyl)tetrahydro-2H-pyran-4-carboxamide | C25H32N2O4
| | |
23 | 945551-93-9 | 945551-93-9 | (1R, 2S)-N, N′-Bis[ (1S)-2-hydroxy-1-phenylmethylethyl ]-3, 3-dimethyl-1, 2-cyclopropanediamide | C25H32N2O4
| | |
24 | 342639-02-5 | Glycine, N-[2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel- (9CI) | Glycine, N-[2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel- (9CI) | C25H32N2O4
| | |
25 | 83968-22-3 | Benzoic acid, 2-hydroxy-, compds. with oxidized N,N-dimethylbenzenamine-N-ethyl-2-methylbenzenamine-formaldehyde reaction products | Benzoic acid, 2-hydroxy-, compds. with oxidized N,N-dimethylbenzenamine-N-ethyl-2-methylbenzenamine-formaldehyde reaction products | C25H32N2O4
| | |